spacer
home > epc > winter 2018 > marking safety
PUBLICATIONS
European Pharmaceutical Contractor

Marking Safety

“Sepsis is the most preventable cause of death” (1), and every hour it is not diagnosed will increase the probability of killing the patient by 7%; thus, recognising the early signs and symptoms is crucial. Severe sepsis is the leading cause of death in the noncoronary intensive care unit, with mortality rates between 30-50%.

According to Dr Adam Linder, “approximately one in five patients with sepsis who are admitted to hospital are at risk of developing severe sepsis within the first 24 hours” (2). Furthermore, it is also the biggest killer of children under five worldwide. Konrad Reinhart notes that 6 million babies from third-world countries and 10,000 of mothers die from the condition every year (1).

As sepsis often impacts the elderly (usually when they have some other condition), it is perhaps less talked about, but it also affects children. With such susceptible groups as these, anything that raises awareness among medical staff of the signs, symptoms, and dangers can only be a good thing.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Professor Christene Leiper attended Sydney University, RMIT Melbourne, and Bond University in Australia and achieved a Professor of Medicine and Life Sciences at Bond University Queensland in 2006. She also undertook research at Edinburgh University, Scotland, as part of her PhD. Christene has been a Principal Investigator for clinical trials, which enables her to operate across many disciplinary boundaries within clinical research in a coherent and productive manner. In 2007, she was appointed Director of Research at a Scottish CRO, which in turn, led her to start her own CRO, Onorach, in 2009.
spacer
Professor Christene Leiper
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PCI Announces Expansion of its Industry-Leading Cold Chain Infrastructure with Dedicated Minus 40 degrees C Facility

Philadelphia, USA – August 29, 2018 PCI Pharma Services (PCI), a full-service provider of specialist outsourced drug manufacturing, Clinical trial services, and commercial packaging to the global healthcare industry, is pleased to announce the completion of a purpose built -40°C storage and distribution facility at its North American Clinical Services Center of Excellence.
More info >>

White Papers

Overcoming research challenges with Adaptive Trials

PCI Pharma Services

There has been cause for concern within the pharmaceutical industry over the last five years, regarding increasing research and development costs, combined with a fall in the number of new drugs brought to market. In an attempt to overcome this issue there has been a significant rise in the use of adaptive clinical trial designs, whilst saving time and money as well as facilitating more effective decision making. One of the biggest challenges that pharmaceutical companies have experienced has been delivering compliant clinical trials supplies across diverse patient populations in the relatively short timeframes that adaptive trial designs require, remaining focused on ensuring that patient compliance and product quality is in no way compromised. This demand has led to the launch of fast response services that support Research and Development in responding to changing dosing regimens mid-trial.
More info >>

 
Industry Events

SAPHEX 2018

1-2 November 2018, Gallagher Convention Centre, Midrand, South Africa

The SAPHEX exhibition and conference is now established as the “go-to” networking and business event for anyone working in the South African pharmaceutical manufacturing industry.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement